Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Radiation Dermatitis Epidemiology Insight Report 2021-2030 Featuring Tempol (APC-400): Adamis Pharmaceuticals/Matrix Biomed and BMX-001: BioMimetix JV - ResearchAndMarkets.com

April 15, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Apr 15, 2021--

The “Radiation Dermatitis - Epidemiology Insight - 2030” report has been added to ResearchAndMarkets.com’s offering.

This ‘Radiation Dermatitis (RD) - Epidemiology Forecast - 2030’ report delivers an in-depth understanding of and historical and forecasted epidemiology of Radiation Dermatitis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Radiation Dermatitis Epidemiology

The RD epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends and assumptions undertaken.

Country-wise Radiation Dermatitis Epidemiology

The epidemiology segment also provides the Radiation Dermatitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total number of incident cases of Radiation Dermatitis associated in 7MM countries was 3,012,048 in 2020.

  • As per the estimates, the United States has the largest incident population of Radiation Dermatitis.
  • Among the EU5 countries, Germany had the highest incident cases of Radiation Dermatitis, followed by France. On the other hand, Spain had the lowest incident cases, with 151,518 cases in 2020.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Radiation Dermatitis Market Overview at a Glance


3.1 Market Share (%) Distribution of Radiation Dermatitis in 2018

3.2 Market Share (%) Distribution of Radiation Dermatitis in 2030

4 Executive Summary of Radiation Dermatitis

5 Disease Background and Overview

5.1 Introduction

5.2 Pathophysiology

5.3 Signs and Symptoms

5.4 Risk Factors

5.5 Types of Radiation Dermatitis (RD)

5.6 Clinical manifestations

5.7 Diagnosis

5.8 Grading

5.9 Differential Diagnosis

5.1 Treatment

5.10.1 Treatment of acute radiodermatitis

5.10.2 Treatment of chronic radiodermatitis

5.19.1 ONS Treatment Guidelines

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Incident Population of Radiation Dermatitis

6.3 Epidemiology of Radiation Dermatitis

6.4 The United States

6.4.1 Radiotherapy Utilization in the United States

6.4.2 Incidence of Radiation Dermatitis in the United States

6.4.3 Grade-specific cases of Radiation Dermatitis in the United States

6.4.4 Treated cases of Radiation Dermatitis in the United States

6.5 EU5

6.5.1 Germany

6.5.2 France

6.5.3 Italy

6.5.4 Spain

6.5.5 United Kingdom

6.6 Japan

7 Organizations contributing towards Radiation Dermatitis

8 Patient Journey

9 Case Reports

10 Emerging Therapies

10.1 Key Cross Competition

10.2 Tempol (APC-400): Adamis Pharmaceuticals/Matrix Biomed

10.2.1 Drug Description

10.2.2 Regulatory Milestones

10.2.3 Clinical Development

10.2.4 Clinical Trials Information

10.2.5 Safety and Efficacy

10.2.6 Product Profile

10.3 BMX-001: BioMimetix JV

11 Radiation Dermatitis: Seven Major Market Analysis

13.1 Key Findings

13.2 Market Size of Radiation Dermatitis in 7MM

13.3 Market Outlook

12 KOL Views

13 Market Drivers

14 Market Barriers

15 SWOT Analysis

16 Unmet Needs

17 Market Access

18 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/loq6sa

View source version on businesswire.com:https://www.businesswire.com/news/home/20210415005580/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 04/15/2021 08:18 AM/DISC: 04/15/2021 08:18 AM